Sitagliptin, an dipeptidyl peptidase-4 inhibitor, does not alter the pharmacokinetics of the sulphonylurea, glyburide, in healthy subjects

AIMS: Sitagliptin, a dipeptidyl peptidase-4 inhibitor, is an incretin enhancer that is approved for the treatment of Type 2 diabetes. Sitagliptin is mainly renally eliminated and not an inhibitor of CYP450 enzymes in vitro. Glyburide, a sulphonylurea, is an insulin sensitizer and mainly metabolized...

Ful tanımlama

Kaydedildi:
Detaylı Bibliyografya
Asıl Yazarlar: Mistry, Goutam C, Bergman, Arthur J, Zheng, Wei, Hreniuk, David, Zinny, Miguel A, Gottesdiener, Keith M, Wagner, John A, Herman, Gary A, Ruddy, Marcella
Materyal Türü: Artigo
Dil:Inglês
Baskı/Yayın Bilgisi: Blackwell Science Inc 2008
Konular:
Pharmacodynamics and Pharmacokinetics
Online Erişim:https://ncbi.nlm.nih.gov/pmc/articles/PMC2485253/
https://ncbi.nlm.nih.gov/pubmed/18503607
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/j.1365-2125.2008.03148.x
Etiketler: Etiketle
Etiket eklenmemiş, İlk siz ekleyin!

Benzer Materyaller